|
 The Drugs Control Officers (India) Welfare Association (DCOIWA) has officially released a comprehensive strategic framework aimed at the total eradication of spurious and substandard medicines across the country.
The policy paper, titled ‘Eradication of Spurious Drugs in India – A Collective Responsibility’, asserts that India’s status as a global pharmaceutical hub necessitates a zero-tolerance policy toward counterfeit drugs to safeguard public health and maintain international trust.
National president of the DCOIWA, G Koteshwar Rao, emphasizes that the fight against fake medicines cannot be the sole burden of government regulators. Instead, the association proposes a multi-stakeholder model that integrates the efforts of industry, healthcare professionals, and the public. This collective approach is designed to create a total surveillance net, moving from reactive enforcement to a proactive, systemic prevention strategy.
A standout feature of the new blueprint is the formalization of pharmaceutical field sales staff as the first line of surveillance. Recognizing that medical representatives and field teams are present in the market daily, the DCOIWA urges the industry to utilize these professionals as ‘eyes and ears’ to report unusual pricing trends or suspicious packaging directly to management and regulators. This ground-level intelligence is viewed as a critical tool for identifying illegal operations before they reach the patient.
On the technological front, the document calls for a massive digital overhaul of the pharmaceutical supply chain. The regulators association advocates for the full-scale implementation of track-and-trace systems, including sophisticated barcoding and QR codes on all medicinal packaging. Further, the association recommends the use of artificial intelligence (AI) and data analytics to scan centralized portals for anomalies, allowing authorities to detect and disrupt illicit distribution networks with surgical precision.
The framework also shifts significant responsibility to the medical community, urging doctors to move beyond simple prescribing. The DCOIWA highlights therapeutic failure, when a drug fails to produce the expected clinical result, as a primary warning sign of a spurious product. Physicians are encouraged to report such failures immediately, providing a clinical feedback loop that can trigger swift regulatory investigations into specific batches or manufacturers.
For consumers, the association offers a stern warning regarding market practices that often lure unsuspecting patients. The document advises the public to buy only from licensed pharmacies and to remain highly sceptical of extreme discounts or unusually low-priced medicines, which are frequently hallmarks of counterfeit products. Vigilance in checking batch numbers, expiry dates, and packaging quality is highlighted as the final barrier in the safety chain.
In his closing statement, Rao called for a unified commitment to ensure that every medicine reaching an Indian patient is safe, effective, and genuine. The DCOIWA’s blueprint insists that through a combination of stringent enforcement of the Drugs and Cosmetics Act, advanced technology, and community-wide alertness, India can eliminate the threat of spurious drugs and secure its position as a world leader in pharmaceutical safety.
|